Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015)

References

• Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004;9(Suppl 5):4–9.
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002;8(4 Suppl):S62–S67.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003 Oct;3(10):721–732.
   PubMed Web of Science ®Google Scholar
• Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000 Jul;2(7):423–427.
   PubMed Web of Science ®Google Scholar
• Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464–468.
   PubMed Web of Science ®Google Scholar
• Hewitson KS, McNeill LA, Riordan MV, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem. 2002;277(29):26351–26355.
   PubMed Web of Science ®Google Scholar
• Quintero M, Mackenzie N, Brennan PA. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol. 2004;30(5):465–468.
   PubMed Web of Science ®Google Scholar
• Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000;14(1):34–44.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Development of novel therapeutic strategies that target HIF-1. Expert Opin Ther Targets. 2006;10(2):267–280.
   PubMed Web of Science ®Google Scholar
• Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res. 2003;93(2):96–105.
   PubMed Web of Science ®Google Scholar
• Teng CM, Wu CC, Ko FN, et al. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol. 1997;320(2–3):161–166.
   PubMed Web of Science ®Google Scholar
• Galle J, Zabel U, Hubner U, et al. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol. 1999;127(1):195–203.
   PubMed Web of Science ®Google Scholar
• DeNiro M, Al-Halafi A, Al-Mohanna FH, et al. Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy. Mol Pharmacol. 2010;77(3):348–367.
   PubMed Web of Science ®Google Scholar
• Chun YS, Yeo EJ, Choi E, et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol. 2001;61(8):947–954.
   PubMed Web of Science ®Google Scholar
• Kuo S-C, Lee F-Y, Teng C-M, et al., inventors; Yung Shin Pharm. Ind. Co., Ltd., Taiwan. assignee. Method for inhibiting EZH2 expression in breast cancer cells using YC-1 (3-(5ʹ-hydroxymethyl-2ʹ-furyl)-1-benzyl indazole) or its succinate ester patent WO2014193930A1. 2014.
   Google Scholar
• Vire E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439(7078):871–874.
   PubMed Web of Science ®Google Scholar
• Deb G, Singh AK, Gupta S. EZH2: not EZHY (easy) to deal. Mol Cancer Res. 2014;12(5):639–653.
   PubMed Web of Science ®Google Scholar
• Al-Mohanna F, Deniro M, inventors; King Faisal Specialist Hospital and Research Centre, Saudi Arabia; Terramark Markencreation GmbH; King Khalid Eye Specialist Hospital. assignee. Pyrazolyl compounds for use in reversing reactive gliosis patent WO2012152295A1. 2012.
   Google Scholar
• Jordan BF, Runquist M, Raghunand N, et al. The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin Cancer Res. 2005;11(2 Pt 1):529–536.
   PubMed Web of Science ®Google Scholar
• Raffel J, Bhattacharyya AK, Gallegos A, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med. 2003;142(1):46–51.
   PubMed Web of Science ®Google Scholar
• Welsh SJ, Williams RR, Birmingham A, et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther. 2003;2(3):235–243.
   PubMed Web of Science ®Google Scholar
• Pearlman E, Leal SM Jr, inventors; Case Western Reserve University, USA. assignee. Thioredoxin protein inhibitors for treatment of fungal infections patent WO2013158892A1. 2013.
   Google Scholar
• Georgopoulos N, inventor; University of Huddersfield, UK. assignee. Composition comprising a tumor necrosis factor receptor (TNFR) agonist and at least one thioredoxin inhibitor for use in the treatment of carcinoma patent WO2014118578A1. 2014.
   Google Scholar
• Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361–371.
   PubMed Web of Science ®Google Scholar
• Welsh S, Williams R, Kirkpatrick L, et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther. 2004;3(3):233–244.
   PubMed Web of Science ®Google Scholar
• Filippini A, Riccioli A, Paone A, et al., inventors; Universita degli Studi di Roma “La Sapienza”, Italy. assignee. Combination of hypoxia-inducible factor-1 inhibitors and toll-like receptor-3 agonists for treating solid tumors patent WO2011128436A1. 2011.
   Google Scholar
• Gordon LI, Evens A, Pestano L, et al., inventors; Northwestern University, USA; Oncothyreon Inc. assignee. PX-478 compositions and methods for treating lymphoma patent WO2011057220A2. 2011.
   Google Scholar
• Peterson S, Pestano L, Fowler K, et al., inventors; Oncothyreon Inc., USA. assignee. Compounds and methods useful for treatment of diseases mediated by HIF-1 patent WO2012058325A1. 2012.
   Google Scholar
• Lee K, Lee JH, Boovanahalli SK, et al. (Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors. J Med Chem. 2007;50(7):1675–1684.
   PubMed Web of Science ®Google Scholar
• Lee K, Kang JE, Park SK, et al. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. Biochem Pharmacol. 2010;80(7):982–989.
   PubMed Web of Science ®Google Scholar
• Lee K, Ban HS, Naik R, et al. Identification of malate dehydrogenase 2 as a target protein of the HIF-1 inhibitor LW6 using chemical probes. Angew Chem Int Ed Engl. 2013;52(39):10286–10289.
   PubMed Web of Science ®Google Scholar
• Kim BS, Lee K, Jung HJ, et al. HIF-1alpha suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1. Biochem Biophys Res Commun. 2015;458(1):14–20.
   PubMed Web of Science ®Google Scholar
• Won M-S, Kim H-M, Lee K, et al., inventors; Korea Research Institute of Bioscience and Biotechnology, S. Korea; Dongguk University Industry-Academic Cooperation Foundation. assignee. Preparation of aryloxyphenoxyacetyl-based compound as hypoxia inducible factor-1 inhibitor for treatment of cancers, diabetic retinopathy and arthritis patent WO2012053768A2. 2012.
   Google Scholar
• Won MS, Lee K, Kim BK, et al., inventors; Korea Research Institute of Bioscience and Biotechnology, S. Korea; Dongguk University Industry-Academic Cooperation Foundation. assignee. preparation of disubstituted adamantyl derivatives as HIF-1 inhibitors for suppressing cancer metastasis patent WO2014084494A1. 2014.
   Google Scholar
• Lee G, Won MS, Kim HM, et al., inventors; Ildong Pharmaceutical Co., Ltd., S. Korea. assignee. HIF-1 α inhibiting compound for angiogenesis-related disease treatment patent KR2015064857A. 2015.
   Google Scholar
• Yin S, Kaluz S, Devi NS, et al. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1alpha interaction with cofactors p300/CBP. Clin Cancer Res. 2012;18(24):6623–6633.
   PubMed Web of Science ®Google Scholar
• Wang W, Ao L, Rayburn ER, et al. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One. 2012;7(9):e44883.
   PubMed Web of Science ®Google Scholar
• Van Meir E, Wang B, inventors; Emory University, USA; Georgia State University Research Foundation. assignee. Preparation of pyranopyridine derivatives for use as HIF inhibitors patent WO2011133659A2. 2011.
   Google Scholar
• Seo YG, Jang DJ, Ahn HC, et al., inventors; SNU R&DB Foundation, S. Korea. assignee. Preparation of deguelin derivatives as HIF-1 inhibitors patent KR2012079274A. 2012.
   Google Scholar
• Chen G, Lu X, Yang J, et al., inventors; Shenyang Pharmaceutical University, Peop. Rep. China. assignee. 2,2-dimethyl benzopyran compounds, the preparation and application patent CN102532082A. 2012.
   Google Scholar
• Wang L, Chen G, Lu X, et al. Novel chalcone derivatives as hypoxia-inducible factor (HIF)-1 inhibitor: Synthesis, anti-invasive and anti-angiogenic properties. Eur J Med Chem. 2015;89:88–97.
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Han GH, Jung HJ, et al., inventors; Industry-Academic Cooperation Foundation, Yonsei University, S. Korea. assignee. Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis patent WO2012124858A1. 2012.
   Google Scholar
• Jung HJ, Kim KH, Kim ND, et al. Identification of a novel small molecule targeting UQCRB of mitochondrial complex III and its anti-angiogenic activity. Bioorg Med Chem Lett. 2011;21(3):1052–1056.
   PubMed Web of Science ®Google Scholar
• Jung HJ, Cho M, Kim Y, et al. Development of a novel class of mitochondrial ubiquinol-cytochrome c reductase binding protein (UQCRB) modulators as promising antiangiogenic leads. J Med Chem. 2014;57(19):7990–7998.
   PubMed Web of Science ®Google Scholar
• Janssen B, Thomson D, Muelbaier M, et al., inventors; Elara Pharmaceuticals GmbH, Germany. assignee. Preparation of bicyclic 2,3-dihydrobenzazine compounds as inhibitors of HIF-mediated transcription and signaling under hypoxic conditions and as cell proliferation and cell division inhibitors patent WO2012130306A1. 2012.
   Google Scholar
• Alonso J, Encinas Lopez A, Muelbaier M, et al., inventors; Elara Pharmaceuticals GmbH, Germany. assignee. Preparation of 2,3-dihydrobenzoxazine and 2,3-dihydrobenzothiazine derivatives as HIF inhibitors useful in treatment and prevention of cancer and inflammatory diseases patent WO2011057892A1. 2011.
   Google Scholar
• Alonso J, Lopez A, Muelbaier M, et al., inventors; European Molecular Biology Laboratory, Germany; Elara Pharmaceuticals GmbH. assignee. Preparation of toluidinylbenzenesulfonamide derivatives for use as HIF-mediated transcription inhibitors patent WO2010075869A1. 2010.
   Google Scholar
• McLaughlin F, Lewis J, inventors; Elara Pharmaceuticals GmbH, Germany. assignee. Compositions comprising docetaxel and a phenylsulfonamide derivative for treatment and prevention of cancer patent WO2012130314A1. 2012.
   Google Scholar
• Toner AP, McLaughlin F, Giles FJ, et al. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance. Br J Cancer. 2013;109(8):2131–2141.
   PubMed Web of Science ®Google Scholar
• Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 2002;62(15):4316–4324.
   PubMed Web of Science ®Google Scholar
• Chau NM, Rogers P, Aherne W, et al. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1 alpha induction in response to hypoxic stress and growth factors. Cancer Res. 2005;65(11):4918–4928.
   PubMed Web of Science ®Google Scholar
• Baker LC, Boult JK, Walker-Samuel S, et al. The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function. Br J Cancer. 2012;106(10):1638–1647.
   PubMed Web of Science ®Google Scholar
• Brown JM, Ahn GO, Kioi M, inventors; Leland Stanford Junior University, USA. assignee. Inhibition of post-radiation tumor growth by inhibiting vasculogenesis by targeting matrix metalloproteinases and bone marrow-derived cells patent US20140086901A1. 2014.
   Google Scholar
• Liang BC, Thornton AF Jr., Sandler HM, et al. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg. 1991;75(4):559–563.
   PubMed Web of Science ®Google Scholar
• Moeller BJ, Cao Y, Li CY, et al. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5(5):429–441.
   PubMed Web of Science ®Google Scholar
• Muelbaier M, Alonso J, Thomson D, et al., inventors; Elara Pharmaceuticals GmbH, Germany. assignee. Preparfation of diazepanyl and piperazinyl imidazo[1,2-a]pyridine compounds as inhibitors HIF-mediated transcription and signaling under hypoxic conditions patent WO2012130322A1. 2012.
   Google Scholar
• Jimenez Barbero J, Lopez Rodriguez ML, Alonso Hernandez D, et al., inventors; Italfarmaco, S.A., Spain. assignee. Preparation of aryl carbamates as inhibitors of fibroblast growth factor patent ES2385160A1. 2012.
   Google Scholar
• Marin-Ramos NI, Alonso D, Ortega-Gutierrez S, et al. New inhibitors of angiogenesis with antitumor activity in vivo. J Med Chem. 2015;58(9):3757–3766.
   PubMed Web of Science ®Google Scholar
• Kim S-W, Kim JH, Kim S-N, et al., inventors; Oscotec Inc., S. Korea. assignee. α-Aryl-β-methoxyacrylate derivative as HIF inhibitor and method for the preparation thereof patent WO2011132967A2. 2011.
   Google Scholar
• Ito D, Nagao S, Yamane Y, et al., inventors; Eisai R & D Management Co., Ltd., Japan. assignee. Preparation of benzanilide derivatives for use as anticancer agents patent JP2011195484A. 2011.
   Google Scholar
• Yasuda Y, Arakawa T, Nawata Y, et al. Design, synthesis, and structure-activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor (HIF)-1 inhibitors. Bioorg Med Chem. 2015;23(8):1776–1787.
   PubMed Web of Science ®Google Scholar
• Crews CM, Buckley D, Ciulli A, et al., inventors; Yale University, USA; GlaxoSmithKline Intellectual Property Development Limited; Cambridge Enterprise Limited University of Cambridge. assignee. Preparation of hydroxyproline analogs as inhibitors of the VCB E3 ubiquitin ligase for treating especially anemia and ischemia patent WO2013106646A2. 2013.
   Google Scholar
• Buckley DL, Van Molle I, Gareiss PC, et al. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1alpha interaction. J Am Chem Soc. 2012;134(10):4465–4468.
   PubMed Web of Science ®Google Scholar
• Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 2003;3(4):363–375.
   PubMed Web of Science ®Google Scholar
• LaVallee TM, Zhan XH, Herbstritt CJ, et al. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res. 2002;62(13):3691–3697.
   PubMed Web of Science ®Google Scholar
• Moser C, Lang SA, Mori A, et al. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer. 2008;8:206.
   PubMed Web of Science ®Google Scholar
• LaVallee TM, Burke PA, Swartz GM, et al. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther. 2008;7(6):1472–1482.
   PubMed Web of Science ®Google Scholar
• Miyamoto T, inventor; Keio University, Japan. assignee. Osteoporosis therapeutic agent, and therapeutic agent screening method patent WO2014104406A1. 2014.
   Google Scholar
• Bai L-P, Parhira S, Zhu G-Y, et al., inventors; Macau University of Science and Technology, Macau. assignee. Preparation of 2ʹ-epi-uscharin from the Latex of Calotropis gigantea with HIF-1 Inhibitory Activity patent AU2014100813A4. 2014.
   Google Scholar
• Chao WR, Amin K, Shi Y, et al. SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo. Angiogenesis. 2011;14(1):1–16.
   PubMed Web of Science ®Google Scholar
• Zhou W, Sambucetti L, inventors; SRI International, USA. assignee. Synergistic anti-cancer activity of SR16388 with anti-mitotic drugs patent WO2013071214A1. 2013.
   Google Scholar
• Chao W-R, Collins N, Sambucetti L, et al., inventors; SRI International, USA. assignee. Compositions and method for the treatment of multiple myeloma comprising (E)-3-hydroxy-21-[2ʹ-(N,N-dimethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene patent US20110257143A1. 2011.
   Google Scholar
• Arora PS, Lao BB, Henchey LK, et al., inventors; University of Southern California, USA; New York University. assignee. Inhibiting interaction between HIF-1α and p300/CBP with hydrogen bond surrogate-based helices using peptidomimetics patent US20150065436A1. 2015.
   Google Scholar
• Arora PS, Olenyuk B, Bullock B, et al., inventors; New York University, USA; University of Southern California. assignee. Preparation of nonpeptidic α-helix mimetic oligooxopiperazines and their use for controlling hypoxia-inducible gene expression patent WO2013123511A1. 2013.
   Google Scholar
• Lao BB, Grishagin I, Mesallati H, et al. In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics. Proc Natl Acad Sci U S A. 2014;111(21):7531–7536.
   PubMed Web of Science ®Google Scholar
• Whitesell L, Mimnaugh EG, De Costa B, et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A. 1994;91(18):8324–8328.
   PubMed Web of Science ®Google Scholar
• Grenert JP, Sullivan WP, Fadden P, et al. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem. 1997;272(38):23843–23850.
   PubMed Web of Science ®Google Scholar
• Supko JG, Hickman RL, Grever MR, et al. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995;36(4):305–315.
   PubMed Web of Science ®Google Scholar
• Schnur RC, Corman ML, Gallaschun RJ, et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem. 1995;38(19):3806–3812.
   PubMed Web of Science ®Google Scholar
• Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 1998;42(4):273–279.
   PubMed Web of Science ®Google Scholar
• Kaur G, Belotti D, Burger AM, et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res. 2004;10(14):4813–4821.
   PubMed Web of Science ®Google Scholar
• Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 2002;62(9):2478–2482.
   PubMed Web of Science ®Google Scholar
• Isaacs JS, Jung YJ, Mimnaugh EG, et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem. 2002;277(33):29936–29944.
   PubMed Web of Science ®Google Scholar
• Liu YV, Baek JH, Zhang H, et al. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell. 2007;25(2):207–217.
   PubMed Web of Science ®Google Scholar
• Cheeseman MT, Brown SDM, inventors; Medical Research Council, UK. assignee. Compounds targeting the VEGF and/or HIF pathway such as sorafenib or vatalanib for use in the treatment of otitis media patent WO2011117568A1. 2011.
   Google Scholar
• Davidson J, Hyde ML, Alberti PW. Epidemiologic patterns in childhood hearing loss: a review. Int J Pediatr Otorhinolaryngol. 1989;17(3):239–266.
   PubMed Web of Science ®Google Scholar
• Kubba H, Pearson JP, Birchall JP. The aetiology of otitis media with effusion: a review. Clin Otolaryngol Allied Sci. 2000;25(3):181–194.
   PubMed Web of Science ®Google Scholar
• Cheeseman MT, Tyrer HE, Williams D, et al. HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants. PLoS Genet. 2011;7(10):e1002336.
   PubMed Web of Science ®Google Scholar
• Huang Q, Zhang Z, Zheng Y, et al. Hypoxia-inducible factor and vascular endothelial growth factor pathway for the study of hypoxia in a new model of otitis media with effusion. Audiol Neurootol. 2012;17(6):349–356.
   PubMed Web of Science ®Google Scholar
• Hardisty-Hughes RE, Tateossian H, Morse SA, et al. A mutation in the F-box gene, Fbxo11, causes otitis media in the Jeff mouse. Hum Mol Genet. 2006;15(22):3273–3279.
   PubMed Web of Science ®Google Scholar
• Parkinson N, Hardisty-Hughes RE, Tateossian H, et al. Mutation at the Evi1 locus in Junbo mice causes susceptibility to otitis media. PLoS Genet. 2006;2(10):e149.
   PubMed Web of Science ®Google Scholar
• Kong D, Park EJ, Stephen AG, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 2005;65(19):9047–9055.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Vogelzang NJ, Kilton LJ, et al. A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study. Invest New Drugs. 1995;13(2):171–174.
   PubMed Web of Science ®Google Scholar
• Chang AY, Kim K, Boucher H, et al. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer. 1998;82(2):292–300.
   PubMed Web of Science ®Google Scholar
• Wadler S, Tenteromano L, Cazenave L, et al. Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemother Pharmacol. 1994;34(3):266–269.
   PubMed Web of Science ®Google Scholar
• Foster BJ, Clagett-Carr K, Shoemaker DD, et al. Echinomycin: the first bifunctional intercalating agent in clinical trials. Invest New Drugs. 1985;3(4):403–410.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Y, Liu Y, et al., inventors; Oncoimmune Inc., USA; Sunvita Therapeutics, Llc. assignee. Uses of hypoxia-inducible factor inhibitors for treating hematol. cancer patent WO2011068563A1. 2011.
   Google Scholar
• Wang Y, Liu Y, Malek SN, et al. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 2011;8(4):399–411.
   PubMed Web of Science ®Google Scholar
• Rao KV, Alvarez FM. Manassantins A/B and saucerneol: novel biologically active lignoids from Saururus cernuus. Tetrahedron Lett. 1983;24(45):4947–4950.
   Web of Science ®Google Scholar
• Hodges TW, Hossain CF, Kim YP, et al. Molecular-targeted antitumor agents: the Saururus cernuus dineolignans manassantin B and 4-O-demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1. J Nat Prod. 2004;67(5):767–771.
   PubMed Web of Science ®Google Scholar
• Hossain CF, Kim YP, Baerson SR, et al. Saururus cernuus lignans–potent small molecule inhibitors of hypoxia-inducible factor-1. Biochem Biophys Res Commun. 2005;333(3):1026–1033.
   PubMed Web of Science ®Google Scholar
• Hwang BY, Lee JH, Nam JB, et al. Lignans from Saururus chinensis inhibiting the transcription factor NF-kappaB. Phytochemistry. 2003;64(3):765–771.
   PubMed Web of Science ®Google Scholar
• Kim JY, Kang JS, Kim HM, et al. Inhibition of phenotypic and functional maturation of dendritic cells by manassantin a. J Pharmacol Sci. 2009;109(4):583–592.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Lu Y, Kwon O, et al. Manassantin A isolated from Saururus chinensis inhibits 5-lipoxygenase-dependent leukotriene C4 generation by blocking mitogen-activated protein kinase activation in mast cells. Biol Pharm Bull. 2011;34(11):1769–1772.
   PubMed Web of Science ®Google Scholar
• Kasper AC, Moon EJ, Hu X, et al. Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations. Bioorg Med Chem Lett. 2009;19(14):3783–3786.
   PubMed Web of Science ®Google Scholar
• Xie P, Chen X, Jiao X, et al., inventors; Institute of Mataria Medica, Chinese Academy of Medical Sciences, Peop. Rep. China. assignee. Saucernetin structurally simplified substances as HIF-1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer patent WO2012163264A1. 2012.
   Google Scholar
• Lang L, Liu X, Li Y, et al. A synthetic manassantin a derivative inhibits hypoxia-inducible factor 1 and tumor growth. PLoS One. 2014;9(6):e99584.
   PubMed Web of Science ®Google Scholar
• Akinboye ES, Bakare O. Biological activities of emetine. Open Nat Prod J. 2011;4:8–15.
   Google Scholar
• Zhou YD, Kim YP, Mohammed KA, et al. Terpenoid tetrahydroisoquinoline alkaloids emetine, klugine, and isocephaeline inhibit the activation of hypoxia-inducible factor-1 in breast tumor cells. J Nat Prod. 2005;68(6):947–950.
   PubMed Web of Science ®Google Scholar
• Ashcroft M, Jones K, inventors; UCL Business PLC, UK. assignee. Antitumor HIF inhibitors patent WO2015079213A1. 2015.
   Google Scholar
• Zhang D, Chen X, Wang C, et al., inventors; Institute of Materia Medica, Chinese Academy of Medical Sciences, Peop. Rep. China. assignee. A Triptolidenol derivative and application as antitumor agents patent CN104513290A. 2015.
   Google Scholar
• Kwon HJ, Lee BR, inventors; Office of Research Affairs/UIF, Yonsei University, S. Korea. assignee. Matairesinol derivatives for inhibiting angiogenesis patent KR2013104769A. 2013.
   Google Scholar
• Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica B. 2015;5(5):378–389.
   PubMed Web of Science ®Google Scholar
• Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell. 2004;6(1):33–43.
   PubMed Web of Science ®Google Scholar
• Shin DH, Chun YS, Lee DS, et al. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood. 2008;111(6):3131–3136.
   PubMed Web of Science ®Google Scholar
• Li SH, Shin DH, Chun YS, et al. A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}. Mol Cancer Ther. 2008;7(12):3729–3738.
   PubMed Web of Science ®Google Scholar
• Koh MY, Powis G. Passing the baton: the HIF switch. Trends Biochem Sci. 2012;37(9):364–372.
   PubMed Web of Science ®Google Scholar
• Zhao J, Du F, Shen G, et al. The role of hypoxia-inducible factor-2 in digestive system cancers. Cell Death Dis. 2015;6:e1600.
   PubMed Web of Science ®Google Scholar
• Dixon DD, Grina J, Josey JA, et al., inventors; Peloton Therapeutics, Inc., USA. assignee. Preparation of aryl ethers as HIF-2α inhibitors and use in treating cancer patent WO2015035223A1. 2015.
   Google Scholar
• Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30(10):1665–1673.
   PubMed Web of Science ®Google Scholar
• Yang L, Xu Y, Li W, et al. Diacylglycerol kinase (DGK) inhibitor II (R59949) could suppress retinal neovascularization and protect retinal astrocytes in an oxygen-induced retinopathy model. J Mol Neurosci. 2015;56(1):78–88.
   PubMed Web of Science ®Google Scholar
• Temes E, Martin-Puig S, Acosta-Iborra B, et al. Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase. J Biol Chem. 2005;280(25):24238–24244.
   PubMed Web of Science ®Google Scholar
• Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134(5):703–707.
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123(9):3664–3671.
   PubMed Web of Science ®Google Scholar
• Li B, Qiu B, Lee DS, et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature. 2014;513(7517):251–255.
   PubMed Web of Science ®Google Scholar